Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Sourij, C; Tripolt, NJ; Aziz, F; Aberer, F; Forstner, P; Obermayer, AM; Kojzar, H; Kleinhappl, B; Pferschy, PN; Mader, JK; Cvirn, G; Goswami, N; Wachsmuth, N; Eckstein, ML; Müller, A; Abbas, F; Lenz, J; Steinberger, M; Knoll, L; Krause, R; Stradner, M; Schlenke, P; Sareban, N; Prietl, B; Kaser, S; Moser, O; Steinmetz, I; Sourij, H, , COVAC-DM, study, group.
Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study.
Diabetes Obes Metab. 2022; 24(5):849-858
Doi: 10.1111/dom.14643
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Sourij Caren
- Sourij Harald
- Tripolt Norbert
- Co-Autor*innen der Med Uni Graz
- Abbas Farah
- Aberer Felix
- Aziz Faisal
- Cvirn Gerhard
- Eckstein Max Lennart
- Forstner Patrick
- Goswami Nandu
- Kleinhappl Barbara
- Knoll Lisa
- Kojzar Harald
- Krause Robert
- Lenz Jacqueline
- Mader Julia
- Moser Othmar
- Müller Alexander
- Pferschy Peter
- Prietl Barbara
- Ramirez-Obermayer Anna Maria Antonia
- Sareban Nazanin
- Schlenke Peter
- Steinmetz Ivo
- Stradner Martin Helmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIMS: To investigate the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and to analyse the response in comparison to individuals without diabetes. MATERIALS AND METHODS: This prospective, multicentre cohort study analysed people with type 1 and type 2 diabetes and a glycated haemoglobin level ≤58 mmol/mol (7.5%) or >58 mmol/mol (7.5%), respectively, and healthy controls. Roche's Elecsys anti-SARS-CoV-2 S immunoassay targeting the receptor-binding domain was used to quantify anti-spike protein antibodies 7 to 14 days after the first and 14 to 21 days after the second vaccination. RESULTS: A total of 86 healthy controls were enrolled in the study, as well as 161 participants with diabetes, of whom 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% of participants in the type 1 diabetes group and 48.0% of those in the type 2 diabetes group showed antibody levels above the cut-off for positivity. Antibody levels after the second vaccination were similar in participants with type 1 diabetes, participants with type 2 diabetes and healthy controls after adjusting for age, sex and multiple testing (P > 0.05). Age (r = -0.45, P < 0.001) and glomerular filtration rate (r = 0.28, P = 0.001) were significantly associated with antibody response. CONCLUSIONS: Anti-SARS-CoV-2 S receptor-binding domain antibody levels after the second vaccination were comparable in healthy controls and in participants with type 1 and type 2 diabetes, irrespective of glycaemic control. Age and renal function correlated significantly with the extent of antibody levels.
- Find related publications in this database (using NLM MeSH Indexing)
- COVID-19 - prevention & control
- COVID-19 Vaccines - therapeutic use
- Cohort Studies - administration & dosage
- Diabetes Mellitus, Type 2 - complications
- Humans - administration & dosage
- Immunity, Humoral - administration & dosage
- Prospective Studies - administration & dosage
- Vaccination - administration & dosage
- Find related publications in this database (Keywords)
- COVID-19
- observational study
- type 1 diabetes
- type 2 diabetes